FDA’s New Guidance on Biomarker and Patient Reported Outcome Qualification

Read more

This brief review will summarize this guidance, outline the mechanism for ensuring DDT qualification, and suggest areas for further elucidation.
This article is taken from the Journal for Clinical Studies, by Henry J. Riordan, Ph.D.


Chief Development Officer

Want to learn more about Worldwide Clinical Trials?